Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus half-dose CAG versus CAG for MDS-EB and AML-MRC
ChiCTR1800019603Phase 4Recruiting
- Sponsor
- Peking University Institute of Hematology
- Start
- Sep 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of decitabine, cytarabine, aclarubicin and granulocyte colony-stimulating factor in myelodysplastic syndrome with excess blasts (MDS-EB) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) (2 arms), sponsored by Peking University Institute of Hematology. Primary endpoint: Complete remission rate. Started Sep 2018; status: recruiting.
02
Drugs
decitabinecytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
myelodysplastic syndrome with excess blasts (MDS-EB)acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)
Beyond the preview
Go deeper on ChiCTR1800019603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019603.